<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="121">
  <stage>Registered</stage>
  <submitdate>4/08/2005</submitdate>
  <approvaldate>4/08/2005</approvaldate>
  <actrnumber>ACTRN12605000072617</actrnumber>
  <trial_identification>
    <studytitle>Glivec plus chemotherapy in blast-phase CML and Ph+ ALL</studytitle>
    <scientifictitle>A Phase II Pilot Study of Glivec (imatinib mesylate formerly known as STI571) Combined with Induction Chemotherapy in Blast-Phase Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, to evaluate safety and improve remission rate.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Australasian Leukaemia and Lymphoma Group (ALLG): ALLG CMLALL1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Blast-Phase Chronic Myeloid Leukemia</healthcondition>
    <healthcondition>Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Combined therapy with Glivec for Philadelphia-chromosome positive leukemias.</interventions>
    <comparator>Conventional chemotherapy for Philadelphia-chromosome positive leukemias.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the safety and tolerability of Glivec (STI571) at 600 mg daily in combination with induction chemotherapy in adult patients with CML in blast crisis or Ph+ ALL during the first 2 months of treatment</outcome>
      <timepoint>During the first 2 months of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. To investigate the efficacy of Glivec combined with induction chemotherapy in Ph+ acute leukaemias. This will be evaluated in terms of response rate (haematological, cytogenetic and molecular)</outcome>
      <timepoint>At 4 weeks, leukaemia-free survival and overall survival at 3 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. To examine the inhibition of Bcr-Abl kinase activity in leukaemic blasts induced in-vivo by Glivec. This will be determined using Western blot analysis.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients with a confirmed diagnosis of Ph+ CML in myeloid or lymphoid blast crisis, defined by the presence of the Philadelphia chromosome or Bcr-Abl fusion transcript and one or both of the following: i) &gt;30% blasts in peripheral blood and/or bone marrow ii) Presence of extramedullary disease other than spleen and/or liver involvement (i.e. chloromas) OR Patients with a confirmed diagnosis of Ph+ ALL 2. Patients of childbearing potential must have a negative pregnancy test prior to the initiation of therapy. Male and female patients agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following the discontinuation of Glivec. 3. Written informed consent.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Exposure to any other investigational agents within 30 days of commencing Glivec 2. Known sensitivity to Glivec or the phenylaminopyrimidine class of drugs 3. ECOG Performance Status Score &gt; 2 (Appendix 1) 4. Left ventricular ejection fraction &lt; 50% on a radionuclide cardiac scan or echocardiogram 5. Creatinine &gt; 1.5 Â´ the upper limit of normal (ULN) at the laboratory where the analysis was performed 6. Serum bilirubin &gt; 2 Â´ ULN 7. AST or ALT  &gt; 2.5 Â´ ULN. In patients with suspected leukaemic involvement of the liver, AST or ALT &gt; 5 Â´ ULN. 8. Known HIV seropositivity 9. Any serious concomitant medical condition that could, in the opinion of the Investigator, compromise participation in the study 10. Pregnancy or breastfeeding 11. Dementia, intellectual impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>3/03/2003</anticipatedstartdate>
    <actualstartdate>18/03/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/02/2007</actualenddate>
    <samplesize>46</samplesize>
    <actualsamplesize>41</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>Jason D Lickliter , Kerry Taylor , Jeff Szer , Andrew Grigg , Christopher Arthur , Timothy P Hughes , Simon Durrant , Robin Filshie , Ian Irving , Michael Seldon , Jennifer Ellacott , Andrew W Boyd , James DRozario , Kim Rooney , Kevin Lynch , and Ken Bradstock , for the Australasian Leukaemia and Lymphoma Group. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosomepositive
acute leukemia: long-term results of the CMLALL1 trial. Leukaemia and Lymphoma 56:630-638 (2015).
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/07/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Private Med Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Melb</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Townsville</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate>12/03/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Kenneth Bradstock</name>
      <address>Haematology Department
Westmead Hospital
Darcy Rd
Westmead NSW 2145</address>
      <phone>+61 2 98457073</phone>
      <fax>+61 2 96892331</fax>
      <email>bradstok@icpmr.wsahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Kenneth Bradstock</name>
      <address>Haematology Department
Westmead Hospital
Darcy Rd
Westmead NSW 2145</address>
      <phone>+61 2 98457073</phone>
      <fax>+61 2 96892331</fax>
      <email>bradstok@icpmr.wsahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>